NexImmune, Yale, and JDRF Extend Research Partnership for Type 1 Diabetes
24 Outubro 2023 - 9:00AM
NexImmune, Inc. (Nasdaq: NEXI) announces the extension of the
research partnership between NexImmune, Yale and JDRF to explore
the use of NexImmune’s AIM nanoparticles in combination with an
anti-CD3 mAb to tolerize, deplete or modulate diabetes
antigen-specific T cells. The extension includes an additional
$300,000 grant, funded by JDRF to Yale, as a part of its Cures
research portfolio, which includes therapies for the prevention of
type 1 diabetes (T1D).
“We are excited with the significant progress by Dr. Kevan
Herold’s lab at Yale, which has led to an additional grant by the
JDRF to investigate our technology in combination with a murine
surrogate of teplizumab, a T cell-specific mAb candidate,” said
Kristi Jones, Chief Executive Officer at NexImmune. “The data
generated to date is encouraging and demonstrate the ability of
NexImmmune’s nanoparticles to specifically inhibit or eliminate
T1D-causing T cells in the lymph node and pancreas.”
The JDRF award will continue to fund efforts to investigate the
use of NexImmune’s AIM nanoparticles in combination with a murine
surrogate of teplizumab, which has been shown to modulate the
pathogenic immune response acutely. Combining anti-CD3 treatment
with NexImmune’s injectable therapy provides the opportunity to
target and modulate T1D antigen-specific T cells and potentially
maintain their non-responsiveness with the goal to extend benefit
and induce tolerance. NexImmune’s nanoparticles have the potential
to further enhance the effect of anti-CD3 through modulation of the
residual T1D specific T cells.
About NexImmune
NexImmune is developing novel approach to immunotherapy designed
to employ the body’s own T cells to generate a specific, potent,
and durable immune response. The backbone of NexImmune’s approach
is a proprietary Artificial Immune Modulation (AIM™) nanoparticle
technology platform. The AIM technology enables NexImmune to
construct nanoparticles that function as synthetic dendritic cells
capable of directing a specific T cell-mediated immune response.
AIM constructed nanoparticles employ natural biology to engage,
activate and expand endogenous T cells in ways that combine
anti-tumor attributes of antigen-specific precision, potency and
long-term persistence with reduced potential for off-target
toxicities. NexImmune is focused on developing injectable AIM
nanoparticle constructs and modalities for potential clinical
evaluation in oncology, autoimmune disorders and infectious
diseases.
For more information, visit www.neximmune.com.
About JDRF
JDRF’s mission is to accelerate life-changing breakthroughs to
cure, prevent and treat T1D and its complications. To accomplish
this, JDRF has invested more than $2.5 billion in research funding
since our inception. We are an organization built on a grassroots
model of people connecting in their local communities,
collaborating regionally for efficiency and broader fundraising
impact, and uniting on a national stage to pool resources, passion,
and energy. We collaborate with academic institutions,
policymakers, and corporate and industry partners to develop and
deliver a pipeline of innovative therapies to people living with
T1D. Our staff and volunteers throughout the United States and our
five international affiliates are dedicated to advocacy, community
engagement and our vision of a world without T1D. For more
information, please visit jdrf.org or follow us on Twitter (@JDRF),
Facebook (@myjdrf), and Instagram (@jdrfhq).
Forward Looking Statements
This press release may contain “forward-looking” statements
within the meaning of the Private Securities Litigation Reform Act
of 1995 that are based on the beliefs and assumptions and on
information currently available to management of the Company. All
statements other than statements of historical fact contained in
this press release are forward-looking statements, including
statements concerning the Company’s ability to regain compliance
with the minimum bid price requirement for continued listing on the
Nasdaq Capital Market; the impact of our workforce reduction; the
enrollment, timing, progress, release of data from and results of
the Company’s paused clinical trials and the expectations with
respect to potential AIM INJ product candidates; the timing,
progress and release of preclinical data from our AIM INJ platform
programs and other preclinical research programs; the expectation
of submitting an IND for NEXI-101 (injectable) in 2024; and the
utility of prior preclinical and clinical data in determining
future clinical results. In some cases, you can identify
forward-looking statements by terminology such as “may,” “will,”
“should,” “expects,” “plans,” “anticipates,” “believes,”
“estimates,” “predicts,” “potential” or “continue” or the negative
of these terms or other comparable terminology. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the Company’s actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risks and uncertainties set forth in
the “Risk Factors” section of our Annual Report on Form 10-K for
the year ended December 31, 2022 filed with the Securities and
Exchange Commission (“SEC”) on March 28, 2023, and subsequent
reports that we file with the SEC. Forward-looking statements
represent the Company’s beliefs and assumptions only as of the date
of this press release. Although the Company believes that the
expectations reflected in the forward-looking statements are
reasonable, it cannot guarantee future results, levels of activity,
performance or achievements. Except as required by law, the Company
assumes no obligation to publicly update any forward-looking
statements for any reason after the date of this press release to
conform any of the forward-looking statements to actual results or
to changes in its expectations.
Contacts:
NexImmune:Chad Rubincrubin@neximmune.com
NexImmune (NASDAQ:NEXI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
NexImmune (NASDAQ:NEXI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024